Found: 4
Select item for more details and to access through your institution.
AN ACTIVE ANTI-AB40 VACCINE (ABVAC40) PROVED TO BE SAFE AND IMMUNOGENIC IN THE PHASE I CLINICAL TRIAL.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P199, doi. 10.1016/j.jalz.2016.06.348
- By:
- Publication type:
- Article
Cognitive composites and prodromal Alzheimer’s disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P707, doi. 10.1016/j.jalz.2015.06.1567
- By:
- Publication type:
- Article
Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0081334
- By:
- Publication type:
- Article
Safety, tolerability and immunogenicity of an active anti-Aβ<sub>40</sub> vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial.
- Published in:
- Alzheimer's Research & Therapy, 2018, v. 10, p. 1, doi. 10.1186/s13195-018-0340-8
- By:
- Publication type:
- Article